A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2013-08-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 58
- Registration Number
- NCT01780259
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT01779791
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 523
- Registration Number
- NCT01776840
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT01767948
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 643
- Registration Number
- NCT01767857
- Locations
- 🇺🇸
The Center for Cancer and Blood Disorders, a Division of Regional Cancer Care Associates LLC., Bethesda, Maryland, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Good Samaritan Hospital Corvallis - SHOC, Corvallis, Oregon, United States
A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT01763021
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
- First Posted Date
- 2012-12-27
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT01756638
A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers
Phase 1
Completed
- Conditions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT01717157
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1209
- Registration Number
- NCT01715285
A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers
Phase 1
Completed
- Conditions
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT01707316
© Copyright 2024. All Rights Reserved by MedPath